Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OptimizeRxOPRX +2.68%56 Equity-to-Asset is 0.80 as of Jun. 2026, which is 3% above its 10-year median of 0.78. GuruFocus rates OPRX with a GF Score™ of 56/100 and a GF Value™ of $11.31 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 684 Healthcare Providers & Services companies, OptimizeRx ranks better than 85.82% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. OptimizeRx's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $131.08 Mil. OptimizeRx's Total Assets for the quarter that ended in Jun. 2026 was $164.32 Mil.
Therefore, OptimizeRx's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.80.
The historical rank and industry rank for OptimizeRx's Equity-to-Asset or its related term are showing as below:
OPRX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.62 Med: 0.78 Max: 0.96
Current: 0.8
During the past 13 years, the highest Equity to Asset Ratio of OptimizeRx was 0.96. The lowest was 0.62. And the median was 0.78.
OPRX's Equity-to-Asset is ranked better than 85.82% of 684
companies
in the Healthcare Providers & Services industry
Industry Median: 0.485
vs OPRX: 0.80
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
OptimizeRx Equity-to-Asset Related Terms
OptimizeRx Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for OptimizeRx's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OPRX vs LFMD, HCAT, DH: Equity-to-Asset Comparison
For the Health Information Services subindustry, OptimizeRx's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OptimizeRx Equity-to-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, OptimizeRx's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OptimizeRx's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OptimizeRx's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OptimizeRx (OPRX) has a Equity-to-Asset of 0.80 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OptimizeRx and its competitors. This is near median its historical median of 0.78. Over the past decade, OptimizeRx's Equity-to-Asset has ranged from 0.62 to 0.96. According to the industry distribution chart, OptimizeRx ranks #97 out of 684 companies in the Healthcare Providers & Services industry, placing it in the top 14.2%.
Is OptimizeRx's Equity-to-Asset too high?
OptimizeRx's current Equity-to-Asset of 0.80 is near median its 10-year median of 0.78. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 0.96. The Healthcare Providers & Services industry median Equity-to-Asset is 0.49. OptimizeRx's value of 0.80 is 64.9% above this industry median. Based on the distribution chart, OptimizeRx ranks #97 out of 684 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, OptimizeRx has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does OptimizeRx's Equity-to-Asset compare to LFMD and HCAT?
According to the Healthcare Providers & Services industry distribution chart, OptimizeRx ranks #97 out of 684 companies for Equity-to-Asset. This places OptimizeRx in the top 14% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.49. OptimizeRx's value of 0.80 is 64.9% above this benchmark. Historically, OptimizeRx's own Equity-to-Asset has ranged from 0.62 to 0.96 over the past decade. While the company's 10-year median is 0.78 vs. the industry median of 0.49, OptimizeRx has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Healthcare Providers & Services company?
The median Equity-to-Asset among Healthcare Providers & Services companies is 0.49, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OptimizeRx's current Equity-to-Asset of 0.80 is 64.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OptimizeRx and its competitors. For the Healthcare Providers & Services industry, the median Equity-to-Asset is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OptimizeRx's current Equity-to-Asset is 0.80, which is near median its own 10-year median of 0.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OptimizeRx stock overvalued right now?
Based on GuruFocus' analysis, OptimizeRx (OPRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.31, compared to a current price of $8.04 — trading 28.9% below its estimated fair value. The current Equity-to-Asset is 0.80, which is near median its 10-year median of 0.78 and 64.9% above the Healthcare Providers & Services industry median of 0.49. OptimizeRx's overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For OptimizeRx (OPRX), the current Equity-to-Asset is 0.80 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OptimizeRx (OPRX) Overvalued in 2026?
Based on GuruFocus' analysis, OptimizeRx stock appears to be undervalued.
The current stock price of $8.04 is trading 28.9% below its estimated GF Value™ of $11.31.
GuruFocus considers OptimizeRx to be Modestly Undervalued.
Key valuation signals for OPRX:
Equity-to-Asset: 0.80 (near median its 10-year median of 0.78)
GF Value™: $11.31 vs. price of $8.04 (28.9% below fair value)
Industry Position: 64.9% above the Healthcare Providers & Services median (#97 of 684)
No single metric tells the full story. See the OPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
56GF Score
Get the complete analysis for OPRX
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPRX has been successfully added to your 
